

## **E2112 STUDY CHAIR - ECOG-ACRIN**

Roisin M. Connolly, MB, BCh, Chair  
Assistant Professor of Oncology  
Johns Hopkins University  
(410) 614-9217  
[rconnol2@jhmi.edu](mailto:rconnol2@jhmi.edu)

## **E2112 STUDY CHAMPIONS**

### **ALLIANCE**

Peter A. Kaufman, MD  
Associate Professor of Medicine  
Dartmouth-Hitchcock Medical Center  
(603) 653-6181  
[peter.a.kaufman@hitchcock.org](mailto:peter.a.kaufman@hitchcock.org)

### **NRG ONCOLOGY**

Alexandra Thomas, MD  
Professor, Hematology Oncology  
Wake Forest University, Cancer Center  
(336) 713-0230  
[althomas@wakehealth.edu](mailto:althomas@wakehealth.edu)

### **SWOG**

Melanie E. Royce, MD, PhD  
Professor of Medicine  
UNM Comprehensive Cancer Center  
Office (505) 925-0416  
Clinic (505) 272-4946

## **E2112 Protocol News - February 2018**

### **UNM, Top Site for E2112 Patient Recruitment, Shares its Model for Success**

Not long after the University of New Mexico (UNM) Comprehensive Cancer Center opened the E2112 trial, it became one of the trial's most consistent enrollers month-to-month. Recently, it achieved status as the top accruer for the trial. We talked with lead investigator Ursa A. Brown-Glaberman, MD, about UNM's patient recruitment practices, as she describes below, that led to the consistently high enrollment.

Every month, breast medical oncologists at UNM discuss the consensus treatment of metastatic hormone receptor-positive (HR+) breast cancer. This has resulted in a consistent group standard for first line therapy, both on and off clinical protocol, evolving over time. The group also routinely biopsies patients, both at the time of presentation and at first relapse with metastatic disease.

During the monthly discussions, the group reviews all breast cancer clinical trials, including those open to metastatic HR+ breast cancer. They display the available trials in a detailed visual algorithm for treatment. Each month, they update the algorithm, distribute it and post it in the clinic.

"Since opening in 2014, E2112 has been our standard 2nd line or later option for metastatic hormone receptor-positive breast cancer," says Dr. Brown-Glaberman. "We have consistently declined other clinical trials in the 2nd line, to avoid competing with E2112."

The group avoids practices that might later exclude patients from E2112. For example, they do not use exemestane in the 1st line setting, and rarely in the adjuvant setting.

"For us, E2112 is a priority NCTN / NCORP trial, with multiple other trials opening and closing in the 1st and 3rd/ later line over the duration," says Dr. Brown-Glaberman.



UNM team photo. Back row: Jill Mauldin, RN (Breast Clinic Nurse), Susan Lopez (Research Coordinator), Ursa Brown-Glaberman, MD (Medical Oncologist). Front row: Leorrie Atencio (Research Coordinator), Priscilla Garcia (Data Coordinator), Karwyn Gustafson, RN (Lead Breast Research Nurse), Ziggy Dayao, MD (Medical Oncologist), Jayne Holmes (Clinic Coordinator).

## 71 more patients left to enroll!




## Top Ten Enrolling Sites

1. University of New Mexico (NM004), Ursa A. Brown-Glaberman, MD (17)
2. Johns Hopkins University (MD017), Roisin M. Connolly, MD (16)
3. Fox Chase Cancer Center (PA086), Jennifer S. Winn, MD, MS (15)
4. Joliet Hematology/Oncology (IL172), Jason Jung-Gon Suh, MD (13)
5. Roswell Park Cancer Center (NY158), Ellis G. Levine, MD (13)
6. Washington University (MO011), Cynthia Xugiang Ma, MD, PhD (13)
7. University of Wisconsin (WI020), Amye J. Tevaarwerk, MD (12)
8. Essentia Health Cancer Center (MN024), Bret E.B. Friday, MD, PhD (11)
9. University of Alabama (AL002), Carla I. Falkson, MD (10)
10. University of Pretoria (63010), Lydia M. Dreosti, MD (10)

## New CIRB-Approved Patient Video!

To assist with patient education when introducing this study, you now have access to a video in which Dr. Connolly explains the trial in lay language. [Click here](#) to view on ecog-acrin.org. Share the link! Need a DVD for local use in your clinic? Send an email to [abricker@ecog-acrin.org](mailto:abricker@ecog-acrin.org).



### PROTOCOL QUESTIONS

Judy Murray, CCRC, Study Chair Liaison  
[jmurra33@jhmi.edu](mailto:jmurra33@jhmi.edu)  
(410) 955-4044

Roisin Connolly, MB, BCh, Chair  
*Contact info is on page one.*

### TRIAD HELP DESK

(703) 390-9858  
[TRIAD-Support@acr.org](mailto:TRIAD-Support@acr.org)

### IMAGE SUBMISSION QUESTIONS

[E2112-Imaging@acrimagemetrix.com](mailto:E2112-Imaging@acrimagemetrix.com)

### MONITORING QUESTIONS

Alison Bricker  
[abricker@ecog-acrin.org](mailto:abricker@ecog-acrin.org)  
(215) 789-3634

### DATA QUESTIONS

Matthew Shimizu [mshimizu@ecog-acrin.org](mailto:mshimizu@ecog-acrin.org)  
Daniel Reeve [dreeve@ecog-acrin.org](mailto:dreeve@ecog-acrin.org)  
(857) 504-2900

### LAB QUESTIONS

ECOG-ACRIN Central Biorepository and Pathology Facility [eacbpf@mdanderson.org](mailto:eacbpf@mdanderson.org)

### NCI TREPTEL LAB

Min-Jung Lee [leemin@mail.nih.gov](mailto:leemin@mail.nih.gov)  
Jane Trepel [trepelj@mail.nih.gov](mailto:trepelj@mail.nih.gov)